We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1,640.50 | 1,640.50 | 1,641.00 | 1,647.00 | 1,634.00 | 1,638.50 | 986,139 | 14:36:20 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.66 | 67.33B |
From Apr 2019 to Apr 2024
By Carlo Martuscelli
German pharmaceutical business Stada Arzneimittel AG said Monday that it is acquiring a portfolio of consumer health-care brands from GlaxoSmithKline for an undisclosed amount.
Stada, which specializes in generic and over-the-counter medicines, said it was purchasing 15 brands, including those specializing in vitamins, cold treatments, and sore throat medication.
The deal is expected to close in the second quarter of the year.
GlaxoSmithKline, a FTSE-100 listed drug maker, announced a strategic re-organization earlier in the month aimed at increasing its focus on high-end research. In December 2018, the company said it would combine its consumer-health division with US rival Pfizer's, to eventually spin off the joint venture. The two-year program aims to prepare for the split in 2022, leaving behind a research-focused biopharmaceutical company.
Write to Carlo Martuscelli at carlo.martuscelli@wsj.com
(END) Dow Jones Newswires
February 24, 2020 07:31 ET (12:31 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
